Introduction
The World Health Organization (WHO) recommends routine viral load (VL) testing to monitor adherence to antiretroviral therapy (ART) and trigger timely treatment switching. 1 
4
VL quantification using plasma samples is the preferred method to quantify VL levels, with whole venous blood requiring shipment to the nearest laboratory for sample preparation within 24 hours. 1 Weak sample transportation systems, however, emerged as an operational barrier in the public sector. 3, 5 Although an alternative approach is on-the-spot venepuncture, plasma separation, and cold-chain storage, 6 it may not be feasible in settings lacking trained human resources, technical supervision, and appropriate laboratory equipment. Expansion of VL testing remains suboptimal and programmatic gaps in VL monitoring persist in many countries. 3, [7] [8] [9] Dried blood spot (DBS) VL quantification, which uses filter paper to collect capillary or venous whole blood, has been proposed as a plasma surrogate to overcome infrastructural, logistic, and operational barriers. 1, 10 However, performance of DBS VL quantification has shown to be suboptimal or lacked generalizability when performed under strictly controlled laboratory conditions. 11-13 Biocentric has recently standardized its HIV-1 viral load assay and made it more automated. 14 To make the assay more RNA-specific and reduce the overestimation of VL with DBS reported in earlier studies, 15 , 16 Biocentric incorporated a DNase pretreatment step to remove HIV-1 proviral DNA prior to nucleic acid amplification.
We assessed the diagnostic accuracy of this novel method under routine clinical conditions and evaluated its field suitability for DBS sample preparation.
Methods

Setting
Routine VL monitoring was introduced in Eswatini (formerly Swaziland) in 2012 using two commercially available platforms (Biocentric and Roche). 8 Findings reported here are part of a larger study assessing the field suitability of the Biocentric methods for plasma and DBS
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5 VL quantification as well as DBS early infant diagnostics in comparison with the national reference method (Roche). Details of the setting and of the evaluation of the Biocentric platform for plasma VL quantification are described elsewhere.
VL platforms
We compared DBS VL quantification using the Biocentric method with plasma VL quantification on two different reference methods.
DBS VL quantification was compared with plasma VL quantification using two different reference methods. The first reference method (RefM-1) is the COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) HIV-1 Test, Version 2.0 (Roche Molecular Diagnostics, Indiana, USA), which operates at the Mbabane laboratory and has a lower limit of detection of 20 copies/mL for plasma VL. It is used for routine plasma VL quantification and is enrolled into the CDC VL testing quality assurance program.
The second reference method (RefM-2) is the Biocentric method using plasma for VL quantification at two locations (Mbabane, Nhlangano) and has been described in detail previously. [17] [18] [19] It is an open real-time PCR platform for HIV-1 RNA quantification of group M (subtype A-H). The method has been recently standardized for regulatory purposes. It received CE certification by a European Notified Body (British Standards Institution) for plasma testing (but not DBS), and uses the Arrow® instrument (DiaSorin, Ireland) for automated nucleic acid extraction and the Fluoroclycler® instrument (Hein Lifescience, Germany) for real-time PCR amplification and detection. The lower limit of detection for plasma VL testing is 416 copies/mL.
After study enrolment, a phlebotomist collected two ethylenediaminetetraacetic acid (EDTA) tubes from venepuncture. Then, the same phlebotomist prepared a DBS filter card containing five spots from the same patient through finger-prick by dropping capillary blood directly onto the paper (DBS-1) without the use of a capillary pipette. Thereafter, a second DBS card was prepared by pipetting 50 µL whole EDTA blood onto the card using a micropipette (DBS-2). The EDTA tubes were sent within 6 hours to the laboratory, where a laboratory technologist prepared another DBS card by pipetting EDTA blood (DBS-3). DBS samples collected at Nhlangano Health Centre were sent to Nhlangano VL laboratory, and samples from Lobamba Clinic were sent to Mbabane VL laboratory. All DBS cards were dried at room temperature for at least 4 hours or overnight, either in the facility (DBS-1, DBS-2) or in the laboratory (DBS-3). Thereafter, they were stored in zip-locked plastic bags with desiccant packs and frozen at -20°C in freezers of the VL laboratories until time of testing between March and May 2018. In addition, EDTA blood from the second tube was centrifuged to obtain plasma for VL quantification on RefM-1 and RefM-2 in Mbabane and Nhlangano.
14 Plasma VL quantification on the reference platforms was performed between November 2016
and April 2017.
The manufacturer trained all laboratory technologists on DBS VL quantification for 3 days.
DBS VL testing was performed on the Biocentric platforms in Nhlangano and Mbabane VL laboratories without the involvement of the manufacturer between March 2017 and May 2018. All laboratory technologists were blinded to the VL results on the reference platform.
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Statistical analysis
Patients with at least one paired plasma and DBS result were included in the study. Patients' baseline characteristics were described with frequency statistics, proportions, and medians with interquartile ranges. The VL values in copies/mL obtained using DBS on the Biocentric platform were multiplied by a 7.5 correction factor that accounts for lost volume during pretreatment of DBS samples, differences in plasma volumes obtained from two DBS spots, the volumes of standards and a 50% hematocrit correction. Sensitivity and specificity estimates as well as positive (PPV) and negative predictive (NPV) values were calculated at the clinical threshold level. For predictive values, we assumed a prevalence of 10% and 30% VL elevations (defined as >1000 copies/mL). Finally, the same analyses were performed at lower threshold levels (200, 400, 600 and 800 copies/mL), and viral failure was assessed at four higher DBS thresholds (2000, 3000, 4000 and 5000 copies/mL) while keeping the plasma threshold constant at 1000 copies/mL. Analyses were performed with Stata v14.1 (StataCorp, Texas, USA). Correlation and agreement Figure 1 shows the correlation graph of paired plasma and DBS values by DBS sampling method and reference method. As Table 2 showed high agreement between DBS and plasma VL testing, with differences ranging from 0.21 to 0.30 log 10 copies/mL for RefM-1 and from 0.15 to 0.25 log 10 copies/mL for RefM-2 (Table 2, Figure 2 ). Table 2 shows diagnostic accuracy estimates which were overall comparable by DBS sampling method and by reference method (95% CI intervals overlapped).
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Diagnostic accuracy
Estimates of the receiver operating characteristic (ROC) area under the curve ranged from 0.90 to 0.93 (ROC curve not shown). Sensitivity estimates ranged from 85.3% to 89.2% for
RefM-1 and from 87.1% to 89.2% for RefM-2. Specificity estimates ranged from 94.5% to 98.6% for RefM-1 and from 94.6% to 97.6% for RefM-2.
The most favorable positive (all ≥87.0%) and negative predictive values (all ≥93.7%) were at the prevalence of 30% VL elevations irrespective of DBS sampling method and reference method. When compared with the prevalence of 10% VL elevations, PPVs were significantly higher for DBS-1 and DBS-2 on both reference methods, and NPVs were significantly lower for DBS-2 and DBS-3 on RefM-1 and for all DBS sampling methods on RefM-2.
Diagnostic accuracy at different threshold levels
For the threshold levels 200, 400, 600, and 800 copies/mL (Supplemental Tables: S-Table 1a, http://links.lww.com/QAI/B339 and S- Table 1b , http://links.lww.com/QAI/B339), sensitivity estimates ranged from 77.2% to 86.6% for RefM-1 and from 81.9% to 87.7% for RefM-2. All specificity estimates remained ≥95% for both reference and all sampling methods.
Comparing the DBS thresholds at 2000, 3000, 4000 and 5000 copies/mL while keeping the plasma threshold constant at 1000 copies/mL, sensitivity estimates tended to be lower and sensitivity estimates slightly higher (S -Table 1a , http://links.lww.com/QAI/B339 and S- Table   1b , http://links.lww.com/QAI/B339). All other estimates (ROC area, NPV, PPV) were also comparable and 95% CI overlapped irrespective of reference method and sampling method.
Considering point estimates only, they tended to be highest at the threshold level of 1,000 copies/mL.
Discordant test results
For 40 (11.0%) patients, at least one paired DBS VL result (DBS-1 and/or DBS-2 and/or DBS-3) did not concur with the plasma VL result of RefM-1 at the threshold level of 1000 copies/mL (discrepant test result) ( Table 3 ). For most of them (n=32, 80.0%), only one corresponding DBS VL result was either upward misclassified (n=23, 57.5%) or downward misclassified (n=9, 22.5%), with the remaining two paired DBS results being concordant with
the plasma VL result. In a few patients, all three corresponding DBS VL results were either upward (n=2, 5.0%) or downward misclassified (n=4, 10.0%).
In comparison with RefM-2, a total of 41 (11.3%) patients had at least one discrepant test result of which 24 (58.5%) were upward misclassified and 7 (17.1%) downward misclassified. All three corresponding DBS VL results were upward or downward misclassified in 2 (4.9%) and 4 (9.8%) patients (see Supplemental Table: S- Table 2, http://links.lww.com/QAI/B339).
Discussion
DBS VL testing has been suggested as one approach to overcome operational barriers in the scale-up of routine VL monitoring in resource-poor settings. 3 This is the first study to date evaluating the performance of venous blood and finger-prick DBS VL quantification with the Biocentric method under routine conditions, using a newly-configured system with a more automated nucleic extraction method and a more RNA-specific DBS VL protocol. In the context of DBS sampling, correlation, sensitivity, and specificity were acceptable and positive, and negative predictive values could be high at the clinical decision making threshold of 1000 copies/mL. We also demonstrated that different DBS sampling procedures could be performed by less qualified health workers.
Findings in context
Other studies have shown that VL assays using DBS samples reached sufficiently high sensitivity at the threshold of 3000 copies/mL or greater. 10 Current 2016 WHO guidelines, however, recommend a lower viral load monitoring threshold (1000 copies/mL) for both plasma and DBS VL results. 1 At this threshold, provisional data showed that the Biocentric remove proviral DNA and improve assay specificity, albeit a reduced sensitivity. 30 In this study, irrespective of DBS sampling and reference methods used, specificity estimates remained stable at the clinical threshold of 1000 copies/mL despite greater variability in sensitivity.
Although diagnostic accuracy at lower threshold levels was comparable with estimates at the 1000 threshold level (95% CIs overlapped), point estimates appeared overall most favorable for the 1000 threshold level. However, robustness of diagnostic performance indicators at lower threshold levels may be limited for RefM-2 because only 7 test results were in the range of 416-999 copies/mL and none were below. Diagnostic test characteristics did also
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14 not improve when assessing viral failure at four higher DBS threshold levels (2000-5000 copies/mL) while keeping the plasma threshold constant at 1000 copies/mL. Given these findings and analytic limitations, it appears more appropriate to apply the viral failure threshold level of 1000 copies/mL for DBS VL quantification in routine settings. Other studies from routine settings also showed that DBS VL quantification potentially performed best at the viral failure threshold level.
15,31
Some VL results were misclassified or discordant. 
Other limitations
Improving the laboratory aspects of VL testing alone is unlikely to achieve programmatic impact and the UNAIDS 90-90-90 targets. Other constraints that need to be tackled include health financing constraints, the lack of appropriate policy frameworks allowing for largescale decentralization of HIV care services, quality of health services and a health workforce with insufficient capacity to implement the clinical aspects of VL monitoring effectively. A strength of this study is that DBS samples were prepared in a routine clinical setting and with involvement of trained lay cadres. In addition, we used filter paper that was already routinely available in this context. Thus, the findings of this study may be generalized to similar settings in Sub-Saharan Africa. Finally, we were able to compare different DBS sampling methods and used two different reference methods. 
Total enrolled 362
Recruiting facilities CI, confidence interval; DBS, dried blood spot sampling; DBS-1, dried blood spot sampling by finger-prick; DBS-2, dried blood spot sampling with whole venous blood by phlebotomist; DBS-3, dried blood spot sampling with whole venous blood by laboratory technologist; IQR, interquartile range; NPV, negative predictive value; PPV, positive predictive value; RefM-1, reference method 1 (Roche, plasma); RefM-2, reference method 2 (Biocentric, plasma); ROC, receiver operating characteristic; VL, viral load. 1 Prevalence of VL elevation was assumed at 10% and 30%.
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Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. 9 Table 3 : Discrepant VL results between plasma VL quantification with RefM-1 and DBS VL quantification (in copies/mL). DBS-1, dried blood spot sampling by finger-prick; DBS-2, dried blood spot sampling with whole venous blood by phlebotomist; DBS-3, dried blood spot sampling with whole venous blood by laboratory technologist; RefM-1, reference method 1.
RefM
A discrepant VL results was defined as a plasma VL result below the clinical threshold of 1000 copies/mL on the reference method (RefM-1) while the VL DBS result was above this threshold, and vice versa.
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whole venous blood by laboratory technologist; n, number; RefM-1, reference method 1 (Roche plasma); RefM-2, reference method 2 (Biocentric plasma).
The Pearson correlation coefficient and fitted regression line were calculated for DBS and plasma samples with VL values above the clinical threshold level (>1000 copies/mL). The correlation estimates for each graph are presented in Table 2 .
whole venous blood by laboratory technologist; RefM-1, reference method 1 (Roche plasma); RefM-2, reference method 2 (Biocentric plasma).
The Bland-Altman plots were calculated for DBS and plasma samples with VL values above the clinical threshold level (>1000 copies/mL). Bland-Altman statistics (average difference and 95% limits of agreement) for for each graph are presented in Table 2 .
